Hepatoma Research
About the journal
Hepatoma Research focuses on research related to liver cancer, biliary tract cancers, and liver diseases. It covers topics such as their occurrence, development, diagnosis, prevention, and treatment. The journal publishes high-quality basic, translational, clinical, and population-based studies across the continuum of liver oncology and related disciplines.
The scope of the journal includes the following areas:
• Liver cancer (primary focus)
Liver cancer, with a focus on hepatocellular carcinoma, including etiologically and biologically defined disease subtypes associated with hepatitis B virus (HBV) and hepatitis C virus (HCV) infection, metabolic dysfunction, inflammation, immune dysregulation, and viral evolution.
Development and validation of diagnostic, prognostic, and predictive biomarkers for liver cancer, including molecular, imaging, and multi-parameter biomarkers relevant to early detection, risk stratification, and assessment of treatment response.
Therapeutic strategies and clinical management of liver cancer, including basic and clinical research on animal models, liver transplantation, surgical and interventional therapies, molecular targeted therapy, immunotherapy, combination treatment strategies, treatment-related drugs and complications, and the clinical translation of emerging laboratory discoveries.
• Biliary tract cancers
Molecular and cellular mechanisms underlying biliary tract cancers, particularly intrahepatic cholangiocarcinoma, with relevance to liver oncology.
Diagnostic, prognostic, and predictive biomarkers for biliary tract cancers.
Clinical management and therapeutic approaches for biliary tract cancers, including surgical, interventional, systemic, and translational treatment strategies.
• Chronic liver diseases associated with liver cancer risk
Chronic liver diseases that are associated with an increased risk of liver cancer include chronic viral hepatitis, metabolic dysfunction–associated steatotic liver disease, alcohol-related liver disease, liver fibrosis, cirrhosis, and immune-mediated liver diseases.
Risk stratification, surveillance strategies, and preventive interventions for liver cancer in patients with high-risk liver diseases.
Translational studies linking chronic liver disease biology to hepatocarcinogenesis and early malignant transformation.
• Epidemiology and public health
Descriptive epidemiological studies of liver cancer and biliary tract cancers, including an analysis of time trends in incidence, mortality, survival, and disease burden (e.g. DALY).
Clinical follow-up or survival studies aimed at evaluating or investigating the prognostic predictive model and the prognostic factors of liver cancer.
Population-based investigations of chronic liver diseases as risk factors for liver cancer.
Predictive risk modeling, public health strategies, and active prevention of liver cancer and biliary tract cancers. Large-scale cohort studies and randomized controlled clinical trials are particularly welcome.
Histopathology of hepatocellular carcinoma - when and what
Understanding immune perspectives and options for the use of checkpoint immunotherapy in HCC post liver transplant
Advances in Y-90 radioembolization for the treatment of hepatocellular carcinoma
Liver Transplantation for perihilar cholangiocarcinoma. Do we need to move forward?
Journal of Cancer Metastasis and Treatment
Metabolism and Target Organ Damage
Hepatoma Research
Editor-in-Chief: Guang-Wen Cao
Indexing: ESCI, CAS, Scopus, Wanfang Data, CNKI, etc.
Median time to first editorial decision: 10 days
Antifibrotic therapy in MASLD: fibrosis reversal and HCC prevention
Gut microbiota in hepatocellular carcinoma: pathogenic mechanisms and clinical translation
Green tea consumption and hepatocellular carcinoma: a meta-analysis lacking evidence for a protective effect
The gut microbiome and the pathogenesis of trans-arterial chemoembolization-associated liver injury
Night shift-induced circadian disruption: links to initiation of non-alcoholic f...
Pathophysiology of liver cirrhosis and risk correlation between immune status an...
Epidemiological characteristics and precise prophylaxis and control of HBV-assoc...
Application of multi-omics in hepatocellular carcinoma: new prospects for classi...
Topic: Fibrosis Driven Hepatocarcinogenesis in MASLD/MASH: Mechanisms, Biomarkers and Therapeutic Horizons
Submission Deadline: 31 Dec 2026 Published articles: 2
Topic: Cancer Stem Cells, Tumor Plasticity, and Tumor Heterogeneity in Hepatocellular Carcinoma
Submission Deadline: 20 Dec 2026 Published articles: 0
Combining Locoregional and Systemic Therapies in Liver Cancer: From Strategy to Survival
Prof. Binyan Zhong
Submission deadline: 30 Jun 2026
Advancing Immunotherapy and Tumor Microenvironment Research in Hepatocellular Carcinoma
Lianxin Liu, MD, PhD
Submission deadline: 15 Nov 2025
Multidisciplinary Management of HCC
Prof. Alessandro Vitale, MD, PhD
Submission deadline: 31 Aug 2025







































































































.jpg)


